AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

The AstraZeneca PLC ADR AZN advanced 1.52% to $69.55 Thursday, on what proved to be an all-around positive trading session ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and ...

LONDON (Reuters) -AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that Europe has stepped up its defence ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and ...

Europe is putting its “ability to protect the health of its own people at risk” by not investing enough, the chief executive ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

Find insight on AstraZeneca, Hartalega and more in the latest Market Talks covering the health care sector.